Sapience Therapeutics, Inc.

Attending #SNO2024 next week? Request a meeting with Abi Vainstein-Haras, MD, our Chief Medical Officer, who is excited to connect with fellow members of the #BrainTumor community at this prestigious event. Click here to send Dr. Vainstein-Haras a meeting request: https://qrco.de/bfDzEr #NeuroOncology #Oncology #Glioblastoma

At #SITC2024, we presented initial clinical pharmacodynamic data from our ST316 Phase 1 study, demonstrating that ST316 dramatically depletes immunosuppressive cells from peripheral blood of patients. These findings were supported by non-clinical studies, where we were pleased to see that treatment with ST316 and PD-1 checkpoint inhibitors had positive effects on tumor outcomes and immune activation. Learn more here: https://lnkd.in/g2tKj76G #SITC2024 #Oncology #CRC #Colorectalcancer #DrugDevelopment

At #SITC2024, we presented additional clinical and biomarker data on ST101, our first-in-class antagonist of C/EBPβ, currently being evaluated in patients with recurrent and newly diagnosed GBM in a Phase 2 dose expansion and Window-of-Opportunity study. Through our Phase 2 and Window-of-Opportunity studies, ST101 has demonstrated impressive disease control as well as modulation of the tumor immune microenvironment (TIME) from immunosuppressive to immune-active. This TIME shift is highly compelling given the immunosuppressive environment that is known to limit the efficacy of immune-oncology (I/O) agents in the treatment of GBM. Learn more here: https://lnkd.in/g2tKj76G #SITC2024 #Oncology #GBM

Exciting updates from #SITC2024! Yesterday, we presented positive clinical data on our lead programs, ST101 and ST316. In an oral presentation, Dr. Jim Rotolo, SVP of Translational Sciences, presented new clinical and biomarker data on ST101 demonstrating activation of the tumor immune microenvironment in glioblastoma (GBM). Dr. Claudio Scuoppo, a Principal Scientist at Sapience, presented initial clinical pharmacodynamic data from our Phase 1 study of ST316, our first-in-class antagonist of the interaction between β-catenin and its co-activator, BCL9. Learn more here: https://lnkd.in/g2tKj76G #SITC2024 #Oncology #GBM #CRC #Colorectalcancer #DrugDevelopment

Later this month, we are looking forward to participating in the Jefferies London Healthcare Conference and engaging with the global biotechnology community in one-on-one meetings. Learn more here: https://lnkd.in/g6HAy-pd #JefferiesHealthcare #Biotech #DrugDiscovery

Today at #SITC2024, we’re honored that Sapience Therapeutics, Inc.’s ST101 abstract will be featured during the conference’s press briefing! Out of over 1,500 abstract submissions, just 8 were featured, representing an array of the top advances in cancer immunotherapy research. We are excited to share the latest clinical and biomarker data from the ST101 GBM window of opportunity study during an oral presentation and poster sessions at this year’s meeting. Click here to learn more: https://lnkd.in/gWPAeQxS #SITC2024 #Oncology #GBM #BrainCancer #DrugDevelopment

As we prepare for #SITC2024, Sapience Therapeutics, Inc. is honored to announce that our ST101 abstract was selected for the conference’s press briefing! Out of over 1,500 abstract submissions, just 8 will be featured at this event, representing an array of the top advances in cancer immunotherapy research. We are excited to share the latest clinical and biomarker data from the ST101 GBM window of opportunity study with this distinguished group. Click here to learn more: https://lnkd.in/gWPAeQxS #Biotech #Oncology #DrugDevelopment

CRC is becoming more deadly for younger patients. In the late 1990s, CRC was the fourth-leading cause of cancer death in both men and women younger than 50 years old. In this age group, CRC is now the top cause of cancer deaths in men and the second-leading cause of cancer deaths in women. At Sapience Therapeutics, Inc., we continue to be committed to advancing therapies for patients with difficult-to-treat cancers. Our first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. Discover how Sapience Therapeutics is advancing the fight against CRC with ST316, and learn more about our Phase 2 Dose Expansion Study here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

Colorectal cancer incidence is on the rise in younger adults. In 1995, the proportion of newly diagnosed patients younger than age 55 was 11%. In 2019, this proportion grew to 20% – nearly doubling. At Sapience Therapeutics, Inc., we are committed to advancing therapies for this devastating disease. Our first-in-class β-catenin antagonist, ST316, selectively targets the Wnt pathway, which drives more than 80% of CRCs. We are currently enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Learn more here: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer

Colorectal cancer (CRC) affects millions of Americans every year. With more than 80% of CRCs estimated to be driven by the Wnt/β-catenin signaling pathway, Sapience Therapeutics, Inc. is proud to advance ST316 - a first-in-class Wnt/β-catenin inhibitor with selective targeting capabilities.   We are currently enrolling CRC patients in a Phase 2 Dose Expansion Study across lines of treatment in combination with standard of care. Discover how Sapience Therapeutics is advancing the fight against CRC with ST316: https://lnkd.in/gpuJBTrn     #FightColorectalCancer #ColorectalCancer